April 2021
Volume 7, Issue 5
This issue examines long-haul COVID-19, central nervous system relapse in non-Hodgkin lymphoma, and more.
Table of Contents
April 2021 Issue
The Agile Advanced Practitioner
In this edition, ASH Clinical News Associate Editor Sandy Kurtin, PhD, ANP-C, AOCN, offers advice for promoting interprofessional agility to keep pace with an...
Editor’s Corner: Post-Pandemia Mania
The severity of the COVID-19 pandemic can hardly be measured – millions have died, billions have been adversely affected, and trillions of dollars have...
April 2021 Issue
Does Elotuzumab Improve PFS in High-Risk Myeloma?
The addition of the anti-SLAMF7 antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and maintenance did not improve outcomes for patients with previously...
How Do Patients With Myeloproliferative Neoplasms Fare After COVID-19 Infection?
Two analyses from the MPN-COVID study from a group of researchers led by Tiziano Barbui, MD, of the United Hospitals of Bergamo in Italy,...
Trilaciclib Approved for Chemotherapy-Induced Myelosuppression
The U.S. Food and Drug Administration (FDA) has approved trilaciclib, a cyclin-dependent kinase 4/6 inhibitor, to reduce the frequency of bone marrow suppression in...
HLA-Haploidentical Relative and Matched Unrelated Donor Transplant Lead to Similar Survival Outcomes in MDS
Transplantation with an HLA-haploidentical relative donor is associated with similar two-year survival rates compared with transplantation with a matched unrelated donor in patients with...
Ixazomib Combination Improves PFS Versus Placebo in Patients With Transplant-Ineligible Myeloma
When researchers added ixazomib to continuous lenalidomide-dexamethasone (Rd) in patients with newly diagnosed, transplant-ineligible multiple myeloma (MM), they observed that the treatment regimen was...
Axicabtagene Ciloleucel Approved for Relapsed/Refractory Follicular Lymphoma
The FDA has approved axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory indolent follicular lymphoma (FL) who have received two...
FDA Grants Breakthrough Therapy Designation to Asciminib for CML
The FDA has granted breakthrough therapy designation to asciminib, a first-in-class allosteric inhibitor specifically targeting the ABL myristoyl pocket (STAMP), for the treatment of...
Melphalan Flufenamide Receives Accelerated Approval for Relapsed/Refractory Multiple Myeloma
Melphalan flufenamide, in combination with dexamethasone, has received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory multiple...
ASH Announces First Round of Research Restart Awardees, 2020 ASH Annual Report Now Available,...
ASH Announces First Round of Research Restart Awardees
The American Society of Hematology (ASH) has announced the names of 19 early-career investigators who will receive critical...
FDA Accepts sNDA for Zanubrutinib in Waldenström Macroglobulinemia
The FDA has accepted a supplemental new drug application (sNDA) for zanubrutinib for the treatment of adults with Waldenström macroglobulinemia (WM).
The sNDA, submitted by...
Transplant Improves Health-Related Quality of Life for Patients With SCD and Transfusion-Dependent Thalassemia
Hematopoietic cell transplantation (HCT) is associated with significant improvements in health-related quality of life (HRQoL) in patients with sickle cell disease (SCD) and transfusion-dependent...
International Working Group Publishes Revised Definitions for Remission, Relapse in Immune TTP
The International Working Group (IWG) for thrombotic thrombocytopenic purpura (TTP) has published revised definitions for response, exacerbation, remission, and relapse of immune-mediated TTP (iTTP)...
Remembering Emil Freireich, Millie Hughes-Fulford, and more
Remembering Emil Freireich (1927 – 2021)
Renowned hematologist and researcher Emil Freireich, MD, died on February 1, 2021, at the age of 93.Dr. Freireich had...
April 2021 Issue
The Long Haul
For some people infected with COVID-19, the disease does not end with the swift resolution of all symptoms.
Last year, Sudipto Mukherjee, MD, MPH, a...
Is Pretransplant Disease Reduction Necessary in MDS and AML?
For patients with myelodysplastic syndromes (MDS) or low-blast secondary acute myeloid leukemia (AML), allogeneic hematopoietic cell transplantation (AHCT) is the only potentially curative treatment...
Examining the Blood-Brain Barrier
The prognosis for patients with non-Hodgkin lymphoma (NHL) who develop central nervous system (CNS) relapse is dismal, and there are few clear answers about...
Pulling Back the Curtain: Vania Hungria, MD, PhD
In this edition, Vania Hungria, MD, PhD, describes her early interest in physical education instruction, her work with the International Myeloma Foundation in Latin...
April 2021 Issue
Reader Responses: How long should a young patient with COVID-19 and pulmonary embolism receive...
Here’s how readers responded to a You Make the Call question about anticoagulation for a young patient with COVID-19 and pulmonary embolism.
Disclaimer: ASH does...
You Make the Call: How long should a young patient with COVID-19 and pulmonary...
This month, Caroline Berube, MD, discusses anticoagulation for a young patient with COVID-19 and pulmonary embolism.
And don't forget to check out next month's clinical...
How I Treat Venous Thromboembolism in Pregnancy
Saskia Middeldorp, MD, PhD, and Wessel Ganzevoort, MD, PhD, discuss the diagnosis, treatment, and prevention of venous thromboembolism in pregnant women. This material is...
